TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01408368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral subtotal thyroidectomy
Description: The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Description: The intervention consisted of total extracapsular thyroidectomy.
Study: NCT04586101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trainings application
Description: Participants have to train with the developed trainings application over six weeks. For this, individual training plans are implemented in the application based on orthopedic joint status and training recommendations of a sports scientist.
Study: NCT04051229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-week exercise training program
Description: Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
Study: NCT01572961

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04269278

Intervention type: DRUG
Intervention: 0 ul of dexmedetomidine
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine

Intervention type: DRUG
Intervention: 0.25 ul of dexmedetomidine
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine

Intervention type: DRUG
Intervention: 0.5 ul of dexmedetomidine
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine

Intervention type: DRUG
Intervention: 0.75 ul of dexmedetomidine
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine
Study: NCT00310427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY686017
Description: 50 mg administered orally on a daily basis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered on a daily basis
Study: NCT01821027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
Study: NCT00905489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine Immediate Release (IR)
Description: 200 mg Tablet or 50 mg / 5 ml oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine Extended Release (XR)
Description: 200 mg, 300 mg or 400 mg Tablet formulation
Study: NCT04140006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN Gel
Description: Flapped surgery for insertion of dental implant with topical application of ALN gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMP Gel
Description: Flapped surgery for insertion of dental implant with topical application of BMP gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Gel
Description: Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Flapped surgery for insertion of dental implant without topical application of any gel
Study: NCT01993420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRM02

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT01317732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOTIONPOD (TM) measures
Description: It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
Study: NCT01832090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse® Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse® Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
Study: NCT04403100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ Ritonavir Oral Tablet
Description: tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets
Description: Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets - 01 tablet twice daily from day 01 through day 10.
Study: NCT02934828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d\*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: postoperative chemotherapy
Description: postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
Study: NCT01300845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Humidification
Description: From randomization, oxygen therapy is humidified

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Humidification
Description: oxygen therapy is never humidified
Study: NCT00270374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Study: NCT03440203

Intervention type: OTHER
Intervention: difficult activities of daily living in each group
Description: Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients

Intervention type: OTHER
Intervention: difficult activities of daily living in each group
Description: Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients

Intervention type: OTHER
Intervention: difficult activities of daily living in each group
Description: Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients
Study: NCT03520283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: System Support Mapping
Description: Complete MAP
Study: NCT01672346

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVAI followed by adenosine provocation
Description: All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVAI followed by adenosine provocation
Description: All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
Study: NCT04051229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized isoenergetic high fat diet
Description: Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
Study: NCT01478568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study: NCT01855126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light
Description: After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red light
Description: After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
Study: NCT00418782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00398359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (physicians)
Description: Identifying and referring children with BMI \>93%.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Modification (families)
Description: Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
Study: NCT01478568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desipramine
Description: oral
Study: NCT02130206

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries Free
Description: Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries Active
Description: Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caries Free - Placebo
Description: Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caries Active - Placebo
Description: Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
Study: NCT05359432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Receiving allocated drug dosage as per clinical needs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Receiving allocated drug dosage as per clinical needs
Study: NCT03201783

Intervention type: OTHER
Group type: OTHER
Intervention: immediate frozen-thawed embryo transfer
Description: Frozen-thawed embryo transfer will be performed in the first cycle following the stimulated IVF cycle

Intervention type: OTHER
Group type: OTHER
Intervention: delayed frozen-thawed embryo transfer
Description: Frozen-thawed embryo transfer will be performed at least in the second cycle following the stimulated IVF cycle
Study: NCT01152281

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maximal Control
Description: 30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrumental and Empowering
Description: Mix of Instrumental and empowering messages with stories of people living with HIV

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Control
Description: Control messages to increase awareness of HIV risk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrumental
Description: Instrumental messages with stories of people living with HIV

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowering
Description: Empowering messages with stories of people living with HIV
Study: NCT02343887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STAI-Y scale for anxiety

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI-Y scale for anxiety

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI-Y scale for anxiety

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beck scale for depression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beck scale for depression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beck scale for depression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without intervention
Study: NCT04034602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration group
Description: plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
Study: NCT00328874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q10
Study: NCT01688037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 25 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 25 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 50 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00368537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
Study: NCT01920412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAmbre Left Atrial Appendage(LAA) Occluder
Description: Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
Study: NCT00228436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study: NCT03185611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: immunomodulator
Study: NCT03863639

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging Procedures
Description: Subjects will complete neuroimaging procedures at 2-6-week postpartum or during hospitalization after delivery prior to discharge, which will consist of high-resolution anatomic, perfusion and resting-brain fMRI sequences; all of which will be acquired on a 3-Tesla General Electric magnetic resonance scanner~provided by the Brain Imaging and Analysis Center (BIAC) at Duke University. No contrast agent will be administered in these imaging procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging Procedures
Description: Subjects will complete neuroimaging procedures at 2-6-week postpartum or during hospitalization after delivery prior to discharge, which will consist of high-resolution anatomic, perfusion and resting-brain fMRI sequences; all of which will be acquired on a 3-Tesla General Electric magnetic resonance scanner~provided by the Brain Imaging and Analysis Center (BIAC) at Duke University. No contrast agent will be administered in these imaging procedures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Assessment Procedures
Description: Once identified as meeting study criteria and consented for participation, parturients will be tested during hospitalization or as outpatients for controls, and at 2-6 weeks postpartum with the following cognitive battery. Wechsler Test of Adult Reading (WTAR), CANTABeclipse Computerized Cognitive Assessment Measures, Stroop Color-Word Test, Controlled Oral Word Association Test, EuroQol, Beck Depression Inventory Revised

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Assessment Procedures
Description: Once identified as meeting study criteria and consented for participation, parturients will be tested during hospitalization or as outpatients for controls, and at 2-6 weeks postpartum with the following cognitive battery. Wechsler Test of Adult Reading (WTAR), CANTABeclipse Computerized Cognitive Assessment Measures, Stroop Color-Word Test, Controlled Oral Word Association Test, EuroQol, Beck Depression Inventory Revised
Study: NCT03162653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
Study: NCT00010335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD34 selection
Description: CD34+ cells are separated from the rest of the peripheral blood stem cells.
Study: NCT02434146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Phenylephrine Solution
Description: Given topically via spray
Study: NCT01932060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin Infusion
Description: Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Infusion
Description: Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
Study: NCT04034602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo group
Description: the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
Study: NCT00912275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib plus oral vinorelbine
Description: Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
Study: NCT00281983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study: NCT01056471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells from adipose tissue.
Description: Intravenous infusion of autologous mesenchymal stem cells.Dose:4\*10e6 cells/Kg.
Study: NCT03185611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: immunomodulator
Study: NCT01056471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells from adipose tissue.
Description: Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
Study: NCT00281983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim